COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
10/03/2026
Nantes, France, March 10, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the transition of Marc Le Bozec from interim to permanent Chief Executive Officer, effective [...]
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
10/03/2026
$12 Million of Tranche Warrants Potential Financing Within One Year From Closing SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a [...]
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
09/03/2026
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward [...]
LifeMD Reports Fourth Quarter and Full Year 2025 Results
09/03/2026
Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million. Successfully launched oral [...]
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
09/03/2026
Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030, a first-in-class [...]
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
09/03/2026
Webcast Scheduled for Monday, March 16 at 8:30 a.m. Eastern CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development [...]
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
09/03/2026
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment WALTHAM, Mass., March 09 [...]
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
09/03/2026
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution [...]
CapsoVision to Participate in the 38th Annual ROTH Conference
09/03/2026
- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 - SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology [...]
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
09/03/2026
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/03/2026
BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has [...]
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
09/03/2026
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
09/03/2026
LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/03/2026
WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
AEON Biopharma Appoints John Bencich as Chief Financial Officer
09/03/2026
Veteran biotechnology leader with extensive capital markets experience joins AEON as Company advances lead asset through key regulatory milestones IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc [...]
Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026
09/03/2026
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report [...]
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
09/03/2026
- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain [...]
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
09/03/2026
CRANFORD, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has extended the expiration date for the exchange offer by the Company [...]
Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
09/03/2026
Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million , driven by growth in MIPLYFFA ® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted [...]

Pages